<DOC>
	<DOCNO>NCT02202551</DOCNO>
	<brief_summary>This 105-week open-label study evaluate safety tolerability ADS-5102 oral capsule , extend release formulation amantadine , Parkinson 's Disease ( PD ) patient Levodopa Induced Dyskinesia ( LID ) .</brief_summary>
	<brief_title>Open-Label Safety Study ADS-5102 PD Patients With LID</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Signed current IRB/REB/IECapproved inform consent form Completed study visit previous Adamas efficacy study ineligible participation previous Adamas study due undergone prior deep brain stimulation . Parkinson 's disease , per UK Parkinson 's Disease Society ( UKPDS ) Brain Bank Clinical Diagnostic Criteria On stable regimen antiparkinson 's medication least 30 day prior screen , include levodopa preparation administer less three time daily . History peak dose dyskinesia might benefit specific dyskinesia treatment judgment subject clinical investigator Discontinued ADS5102 previous Adamas efficacy study due intolerable unacceptable AEs consider related ADS5102 History neurosurgical intervention relate Parkinson 's disease , exception deep brain stimulation History seizures since completion participation previous Adamas study within 2 year History stroke TIA since completion participation previous Adamas study within 2 year History cancer since completion participation previous Adamas study within 2 year , follow exception : adequately treat nonmelanomatous skin cancer , localize bladder cancer , nonmetastatic prostate cancer situ cervical cancer Presence cognitive impairment , evidence MiniMental Status Examination ( MMSE ) score less 24 screening If female pregnant lactating If sexually active female , surgically sterile least 2 year postmenopausal , agree utilize effective method contraception screen least 4 week completion study treatment . Treatment investigational drug ( ADS5102 ) device within 30 day prior screen Treatment investigational biologic within 6 month prior screen Current plan participation another interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Levodopa Induced Dyskinesia</keyword>
	<keyword>LID</keyword>
	<keyword>Parkinsonism</keyword>
	<keyword>Parkinson 's Disease</keyword>
</DOC>